These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 10954961)

  • 21. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
    Nightingale CH
    Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
    Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
    Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the clinical microbiology profile of moxifloxacin.
    Krasemann C; Meyer J; Tillotson G
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S51-63. PubMed ID: 11249830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluoroquinolones in respiratory infections.
    Klein NC
    Semin Respir Infect; 1991 Sep; 6(3):131-5. PubMed ID: 1754733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Moxifloxacin--a new fluoroquinolone antibacterial.
    Drug Ther Bull; 2004 Aug; 42(8):61-2. PubMed ID: 15310155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute, bacterial maxillary sinusitis in adults.
    Klossek JM; Siegert R; Nikolaidis P; Arvis P; Leberre MA;
    J Laryngol Otol; 2003 Jan; 117(1):43-51. PubMed ID: 12590855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Moxifloxacin--a novel antimicrobial preparation for treatment of respiratory infections].
    Iakovlev SV; Polushkina NR; Iakovlev VP
    Ter Arkh; 2001; 73(11):15-22. PubMed ID: 11806197
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
    Noreddin AM; Reese AA; Ostroski M; Hoban DJ; Zhanel GG
    Clin Ther; 2007 Dec; 29(12):2685-9. PubMed ID: 18201584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
    Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
    Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical contribution of the newer fluoroquinolones in acute bacterial exacerbation of chronic bronchitis].
    Niederman MS
    Medicina (B Aires); 1999; 59 Suppl 1():23-30. PubMed ID: 10436551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moxifloxacin.
    Balfour JA; Wiseman LR
    Drugs; 1999 Mar; 57(3):363-73; discussion 374. PubMed ID: 10193688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The role of quinolones in the treatment of community acquired pneumonia].
    Garau J
    Med Clin (Barc); 1998 Feb; 110 Suppl 1():31-5. PubMed ID: 9717158
    [No Abstract]   [Full Text] [Related]  

  • 35. A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP).
    Ferrara AM
    Clin Interv Aging; 2007; 2(2):179-87. PubMed ID: 18044134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of worldwide experience with sparfloxacin in the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis.
    Finch RG
    Int J Antimicrob Agents; 1999 Jun; 12(1):5-17. PubMed ID: 10389642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis.
    Schaberg T; Ballin I; Huchon G; Bassaris H; Hampel B; Reimnitz P;
    J Int Med Res; 2001; 29(4):314-28. PubMed ID: 11675905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of sequential moxifloxacin for treatment of community-acquired pneumonia associated with atypical pathogens.
    Hoeffken G; Talan D; Larsen LS; Peloquin S; Choudhri SH; Haverstock D; Jackson P; Church D
    Eur J Clin Microbiol Infect Dis; 2004 Oct; 23(10):772-5. PubMed ID: 15605184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A comparison of moxifloxacin and amoxicillin in the treatment of community-acquired pneumonia in Latin America: results of a multicenter clinical trial].
    Jardim JR; Rico G; de la Roza C; Obispo E; Urueta J; Wolff M; Miravitlles M;
    Arch Bronconeumol; 2003 Sep; 39(9):387-93. PubMed ID: 12975069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Moxifloxacin: results of clinical use].
    Iakovlev VP; Polushkina NR
    Antibiot Khimioter; 2002; 47(10):32-6. PubMed ID: 12674792
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.